BrainsWay partners with Mindful Health Solutions network

BrainsWay Ltd. (BWAY) partnered with Mindful Health Solutions, a behavioral health provider, to expand access to its Deep TMS and SWIFT treatments. The collaboration includes education initiatives and research. BrainsWay also invested $0.8M in Heading Health's management services organization. The company develops neuromodulation therapies for mental health disorders, with FDA clearance for three indications.

Original reporting
Published Nov 2, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BWAY
Neutral
medium confidence
Mentioned
$BWAY
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BWAYNeutralLow
01

Why it matters

The collaboration aims to increase patient access and explore at‑home neuromodulation, which could broaden BrainsWay's addressable market.

02

Market read

Strategic partnership with modest immediate impact; primarily a long‑term growth catalyst for BrainsWay.

03

What to watch

Potential regulatory hurdles for new treatment protocols and competition from other neuromodulation technologies.

Relevance 5/10Novelty 5/10Timing: today

Background

BrainsWay develops FDA‑cleared Deep Transcranial Magnetic Stimulation devices for depression, OCD, and smoking cessation. Mindful Health Solutions operates a network of brain‑medicine clinics.

Company-level read

Ticker impact

$BWAYNeutralMedium confidence
Context

BrainsWay announced a new collaboration with Mindful Health Solutions to expand access to its Deep TMS technology and explore neuromodulation therapies.

Expected impact

potential modest upside as investors price in expanded patient access and pipeline synergies.

Evidence & confidence

The deal is a strategic alliance without disclosed cash, so impact is limited to longer‑term growth expectations.

Market effects

May signal increased interest in non‑pharmacologic mental‑health treatments, potentially benefiting other TMS and neuromodulation firms.

Limited to U.S. and Israeli markets where BrainsWay operates.

Low, as the partnership is niche and does not affect broader market indices.

Counterpoint

Without disclosed financial terms, the partnership may not translate into meaningful near‑term revenue, limiting upside.

Key entities

  • BrainsWay Ltd.

    NASDAQ‑listed developer of Deep TMS technology.

  • Mindful Health Solutions

    Provider of behavioral health and interventional psychiatry services.

Related articles

$BWAYMed

Brainsway Ltd. (BWAY): Financial results for Q3 2026

Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights Revenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 million Remaining performance

$BWAYMedAI 8/10

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

BrainsWay Ltd. (NASDAQ: BWAY) reported results from a pilot study on its Deep TMS™ technology in patients with depression and early-stage Alzheimer’s disease. The study showed an 83.3% response rate and 50% remission rate in depressive symptoms, with measurable changes in brain activity. The study was published in the Journal of Geriatric Psychiatry and Neurology.

$BWAYMedAI 8/10

Brainsway Q2 Earnings Call Highlights

BrainsWay (NASDAQ:BWAY) reported Q2 gross profit up 34% to $12.8M with gross margin at 75%. Management cited a 30% backlog increase and SWIFT reimbursement progress, estimating 57M US covered lives. CFO Ido Marom said operating cash flow was $6.3M and raised 2026 revenue guidance to $68M-$70M. The company is also discussing Neurolief’s ProlivRx soft launch.